EP2698634A4 - Biomarker for breast cancer - Google Patents

Biomarker for breast cancer

Info

Publication number
EP2698634A4
EP2698634A4 EP12770851.9A EP12770851A EP2698634A4 EP 2698634 A4 EP2698634 A4 EP 2698634A4 EP 12770851 A EP12770851 A EP 12770851A EP 2698634 A4 EP2698634 A4 EP 2698634A4
Authority
EP
European Patent Office
Prior art keywords
biomarker
breast cancer
breast
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12770851.9A
Other languages
German (de)
French (fr)
Other versions
EP2698634B1 (en
EP2698634A1 (en
Inventor
Hitoshi Endou
Isao Okayasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J Pharma Co Ltd
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Publication of EP2698634A1 publication Critical patent/EP2698634A1/en
Publication of EP2698634A4 publication Critical patent/EP2698634A4/en
Application granted granted Critical
Publication of EP2698634B1 publication Critical patent/EP2698634B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
EP12770851.9A 2011-04-15 2012-04-13 Biomarker for breast cancer Active EP2698634B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011091378 2011-04-15
PCT/JP2012/060114 WO2012141285A1 (en) 2011-04-15 2012-04-13 Biomarker for breast cancer

Publications (3)

Publication Number Publication Date
EP2698634A1 EP2698634A1 (en) 2014-02-19
EP2698634A4 true EP2698634A4 (en) 2014-11-26
EP2698634B1 EP2698634B1 (en) 2017-11-08

Family

ID=47009444

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12770851.9A Active EP2698634B1 (en) 2011-04-15 2012-04-13 Biomarker for breast cancer

Country Status (7)

Country Link
US (1) US9618512B2 (en)
EP (1) EP2698634B1 (en)
JP (1) JP6075881B2 (en)
KR (1) KR101976219B1 (en)
CN (1) CN103547923B (en)
ES (1) ES2656988T3 (en)
WO (1) WO2012141285A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103808937B (en) * 2014-03-13 2015-11-18 广州恒泰生物科技有限公司 For breast cancer early metaphase quick diagnosis reagent kit and detection method thereof
US20150285803A1 (en) * 2014-04-08 2015-10-08 Invivis Pharmaceuticals Inc. Systems and methods for identifying progesterone receptor subtypes
KR20170084086A (en) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 Onapristone extended-release compositions and methods
CN105934672A (en) * 2014-12-22 2016-09-07 J制药股份有限公司 circulating biomarker for cancer
JP2018528944A (en) 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド Method for producing onapristone intermediate
JP6599710B2 (en) * 2015-09-29 2019-10-30 公益財団法人ヒューマンサイエンス振興財団 Cocktail antibody
CN105238763A (en) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 Anti-PR protein monoclonal antibody hybridomas cell, anti- PR monoclonal antibody generated by same and application
KR20180113988A (en) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 Amorphous Ona Pristone Composition and Method of Manufacturing the Same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN107200779B (en) * 2017-07-03 2020-04-03 中国农业大学 Preparation method and application of β cell strain for stably over-expressing LAT3
CN110215448B (en) * 2018-03-02 2022-09-20 中国医学科学院基础医学研究所 Drug containing transport protein inhibitor, pharmaceutical composition and application
JP2019158777A (en) * 2018-03-16 2019-09-19 東ソー株式会社 Tumor marker and method for collecting and detecting tumor cell by distinguishing it from contaminant cell
IT201800004137A1 (en) * 2018-03-30 2019-09-30 Domenico Marina Di IN VITRO SCREENING METHOD FOR EARLY DIAGNOSIS OF TUMORS OF THE ORAL CAVITY AND RELATED KIT, BASED IN PARTICULAR ON THE ELISA ASSAY
CN110376036A (en) * 2019-07-30 2019-10-25 河南赛诺特生物技术有限公司 A kind of preparation method and tumor cell line immunohistochemistry reference substance of tumor cell line immunohistochemistry reference substance
KR20220141216A (en) 2021-04-12 2022-10-19 연세대학교 산학협력단 A Novel Biomarker for Diagnosing Breast Cancer
CN116333115B (en) * 2023-05-12 2023-07-28 北京纳百生物科技有限公司 Anti-progesterone monoclonal antibody, kit and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000342270A (en) * 1999-06-04 2000-12-12 Japan Science & Technology Corp Neutral amino acid transporter having broad substrate selectivity and its gene
EP1111048A2 (en) * 1998-09-03 2001-06-27 Japan Science and Technology Corporation Neutral amino acid transporter and gene thereof
EP2146208A1 (en) * 2007-02-06 2010-01-20 J-Pharma Co., Ltd. Kit for deciding degree of malignancy in prostate cancer and method of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698410A (en) 1995-06-07 1997-12-16 Mount Sinai School Of Medicine Of The City University Of New York Highly sensitive immunocytochemical method for diagnosis of malignant effusions
JP4592131B2 (en) 1999-08-05 2010-12-01 ジェイファーマ株式会社 Transporter using cystine, basic amino acid and neutral amino acid as substrate and its gene
JP2001228146A (en) 1999-12-07 2001-08-24 Takeda Chem Ind Ltd Use of disease-associated gene
JP2001211886A (en) 2000-02-07 2001-08-07 Japan Science & Technology Corp Non-sodium-dependent small neutral amino acid transporter transporting l- and d-amino acids and its gene
JP3507884B2 (en) 2000-03-07 2004-03-15 新潟大学長 Objective diagnosis of schizophrenia using gene expression as an index
TWI390034B (en) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB2460769C (en) * 2007-11-30 2011-09-07 Applied Genomics Inc TLE3 as a marker for chemotherapy
JP2011024537A (en) * 2009-07-29 2011-02-10 Kinki Univ Antibody against transporter, and use of the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1111048A2 (en) * 1998-09-03 2001-06-27 Japan Science and Technology Corporation Neutral amino acid transporter and gene thereof
JP2000342270A (en) * 1999-06-04 2000-12-12 Japan Science & Technology Corp Neutral amino acid transporter having broad substrate selectivity and its gene
EP2146208A1 (en) * 2007-02-06 2010-01-20 J-Pharma Co., Ltd. Kit for deciding degree of malignancy in prostate cancer and method of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012141285A1 *

Also Published As

Publication number Publication date
ES2656988T3 (en) 2018-03-01
US20140106377A1 (en) 2014-04-17
CN103547923A (en) 2014-01-29
US9618512B2 (en) 2017-04-11
EP2698634B1 (en) 2017-11-08
KR101976219B1 (en) 2019-05-07
EP2698634A1 (en) 2014-02-19
JPWO2012141285A1 (en) 2014-07-28
WO2012141285A1 (en) 2012-10-18
KR20140019833A (en) 2014-02-17
JP6075881B2 (en) 2017-02-08
CN103547923B (en) 2015-08-12

Similar Documents

Publication Publication Date Title
EP2698634A4 (en) Biomarker for breast cancer
HK1193637A1 (en) Biomarkers for lung cancer
EP2718721A4 (en) Circulating biomarkers for cancer
HK1210832A1 (en) Cancer diagnostics using biomarkers
HK1197182A1 (en) Cancer immunotherapy
EP2825674A4 (en) Thyroid cancer biomarker
HUE046152T2 (en) Individualized vaccines for cancer
IL225441A0 (en) Breast cancer diagnostics
ZA201205003B (en) Methods for treating breast cancer
GB2513275B (en) Biomarkers for Breast Cancer Prediction and Diagnosis
PL2931922T3 (en) Personalized biomarkers for cancer
IL237436A0 (en) Method for screening cancer
EP2861766A4 (en) Methylation biomarkers for breast cancer
GB201012590D0 (en) Methods for diagnosing cancer
GB201120860D0 (en) Cancer immunotherapy
EP2686447A4 (en) Prognostic marker sets for prostate cancer
EP2758777A4 (en) Detecting ovarian cancer
EP2894477A4 (en) Method for determining breast cancer
EP2742358A4 (en) Methods for diagnosing cancer
GB2510539B (en) Biomarkers of cancer
EP2753716A4 (en) Novel risk biomarkers for lung cancer
EP2649225A4 (en) Biomarkers for prediction of breast cancer
GB201104556D0 (en) Biomarkers
EP2732287A4 (en) Methods of diagnosing cancer
GB201201466D0 (en) Breast enhancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141024

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20141020BHEP

Ipc: G01N 33/48 20060101ALI20141020BHEP

Ipc: G01N 33/53 20060101ALI20141020BHEP

Ipc: G01N 33/574 20060101AFI20141020BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170523

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 944627

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012039528

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FREIGUTPARTNERS IP LAW FIRM DR. ROLF DITTMANN, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2656988

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180301

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171108

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 944627

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171108

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180208

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180208

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180308

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180209

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012039528

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171108

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200629

Year of fee payment: 9

Ref country code: CH

Payment date: 20200420

Year of fee payment: 9

Ref country code: DE

Payment date: 20200420

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200427

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012039528

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211103

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210413

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210414

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230426

Year of fee payment: 12

Ref country code: FR

Payment date: 20230424

Year of fee payment: 12